Advertisement

Topics

Breast cancer: What lies beyond APHINITY for HER2-positive breast cancer?

07:18 EDT 9 Aug 2017 | Nature Publishing

Potential strategies for improving the outcomes of patients with early stage HER2-positive (HER2+) breast cancer have included dual anti-HER2 therapy. Recent results from the APHINITY trial show a statistically significant, but clinically modest, benefit from the addition of pertuzumab to trastuzumab and chemotherapy. Subsequent trials should focus on biomarkers to identify patients with HER2+ breast cancer who require more-intensive or less-intensive therapy.

Original Article: Breast cancer: What lies beyond APHINITY for HER2-positive breast cancer?

NEXT ARTICLE

More From BioPortfolio on "Breast cancer: What lies beyond APHINITY for HER2-positive breast cancer?"

Quick Search
Advertisement
 

Relevant Topics

Breast Cancer
Track and monitor developments in breast cancer research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on breast cancer and follow companies active in the development of breast cancer tr...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...